Spectral AI, Inc.

As of November 14, 2023, Spectral AI, Inc. is considered risky and overvalued due to negative valuation ratios and underperformance compared to peers, despite a strong one-year return of 88.89% that contrasts with its year-to-date decline of 21.91%.

As of November 14, 2023, Spectral AI, Inc. is rated as risky and overvalued due to its negative P/E ratio of -5.80, a troubling price-to-book value of -31.67, and an underperformance of -27.56% year-to-date compared to the S&P 500's 2.44%.

As of June 4, 2025, Spectral AI, Inc. shows a mildly bullish trend overall, supported by the weekly MACD and Bollinger Bands, despite mixed signals from daily moving averages and the KST.

Spectral AI, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $7 million and a net profit of $3 million. It has a market cap of $51.49 million and a return on equity of 545.69%.

As of Jun 18, Spectral AI, Inc. has a market capitalization of 51.49 million, with net sales of 29.96 million and a net profit of -9.20 million over the last four quarters. Shareholder's funds are -7.25 million, and total assets are 12.10 million.